Trial Profile
A Phase 1 Trial of BNC105P & Ibrutinib in Patients with Relapsed/Refractory chronic lymphocytic leukemia (CLL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs BNC 105 (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 03 Jan 2023 Status changed from active, no longer recruiting to completed.
- 09 Aug 2022 Planned End Date changed from 1 Jun 2022 to 1 Jan 2023.
- 21 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.